RecruitingNot ApplicableNCT06191731

Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations


Sponsor

Centre Hospitalier Régional Metz-Thionville

Enrollment

60 participants

Start Date

Apr 12, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a single-center cohort study aimed to describe the urinary excretion kinetics of gadolinium contrast agents (Gd-CAs). Patients with a prescription for injected MRI are invited to participate in the study. If they agree, blood and urine samples are collected before Gd-CAs injection, and urine samples are collected between 0- and two-and-a-half-hours post-injection of Gd-CAs.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patients:
  • over 18 years of age
  • with a prescription for MRI with gadolinium-based contrast agents (Gd-CAs) injection validated by a radiologist
  • affiliated with a health insurance plan
  • have signed an informed consent form

Exclusion Criteria10

  • Patients:
  • with known allergy to gadolinium-based contrast agents (Gd-CAs)
  • with known severe renal impairment (GFR < 30 mL/min)
  • on dialysis
  • with urinary incontinence
  • with an ongoing urinary tract infection
  • under hydric or hydrosodic restriction
  • unable to urinate independently
  • Protected persons (under guardianship, curatorship or safeguard of justice)
  • Pregnant or breast-feeding women

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERbiological samples collection

Urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs.


Locations(1)

CHR Metz-Thionville/Hopital de Mercy

Metz, Grand Est, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06191731


Related Trials